Generation Bio Co. Stock Price, News & Analysis

Generation Bio (Nasdaq: GBIO) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2023, at 4:30 p.m. PST in San Francisco, CA. The company focuses on innovative genetic medicines targeting rare and prevalent diseases. A live webcast of the presentation will be available on the investor section of their website. Generation Bio's platform features unique technologies designed to enable durable, redosable treatments with large genetic payloads for specific cell types.

Generation Bio Co. (Nasdaq: GBIO) reported a cash position of $301.2 million as of September 30, 2022, expected to fund operations into 2025. The company focuses on developing genetic medicines, particularly for hemophilia A, utilizing its proprietary delivery system. Third quarter R&D expenses totaled $21.2 million, down from $22.0 million the previous year, while G&A expenses rose to $11.5 million, up from $9.7 million. The net loss narrowed to $31.3 million or $0.53 per share, compared to $31.9 million or $0.56 per share a year ago.

Generation Bio Co. (Nasdaq: GBIO) will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on September 29th at 10:30 a.m. ET in New York. A live webcast will be available on the company's investor website, and a replay will be accessible for 30 days post-event.

Generation Bio focuses on developing genetic medicines for rare and prevalent diseases using its unique platform, which includes closed-ended DNA (ceDNA) technology and a scalable manufacturing process. The aim is to provide durable, redosable treatments for patients worldwide.

Generation Bio Co. (Nasdaq: GBIO) has promoted Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa, who joined the company in 2017, will lead corporate strategy and business development. His previous experience includes co-founding Generation Bio and roles at Merck and Flagship Pioneering. The company is focused on innovating genetic medicines using non-viral DNA therapeutics and targeted lipid nanoparticle delivery. Generation Bio aims to increase the availability of genetic medicines through its scalable manufacturing processes and unique technology platform.

Generation Bio Co. (Nasdaq: GBIO) reported second quarter 2022 financial results, focusing on advancements in its genetic medicine platform. The company has a cash balance of $312.2 million, projected to fund operations into 2025. Key developments include a new modular manufacturing strategy for its closed-ended DNA (ceDNA) product, enhancing productivity and capital efficiency. The net loss for the quarter increased to $37.9 million, or $0.66 per share, compared to $30.8 million or $0.55 per share in the previous year.

Generation Bio Co. (Nasdaq: GBIO) announced its participation in the virtual 2022 Wedbush PacGrow Healthcare Conference scheduled for August 9th at 9:45 a.m. ET. The event will include a live webcast available on the company’s investor website, with a replay accessible for 30 days post-event. Generation Bio is focused on advancing genetic medicines using its unique non-viral platform, which aims to provide durable, redosable treatments for rare and prevalent diseases, utilizing innovative technologies like closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticles.

Generation Bio (Nasdaq: GBIO) announced the appointment of Dannielle Appelhans to its Board of Directors on July 18, 2022. Appelhans, currently COO of Rubius Therapeutics, brings extensive experience in pharmaceutical strategy and operations, including leadership roles at Novartis. Her expertise is expected to aid Generation Bio as it transitions from research to commercialization. Appelhans expressed enthusiasm about contributing to the company's mission of developing novel genetic medicines for rare diseases.

Generation Bio (Nasdaq: GBIO) is revising its GMP manufacturing strategy to optimize efficiency through enhanced rapid enzymatic synthesis (RES) of closed-ended DNA (ceDNA). The company will sublease its planned GMP facility and adopt a smaller, flexible manufacturing footprint, extending its cash runway into 2025. This shift will not affect production timelines for its ongoing liver, retina, and vaccine programs. The RES process allows for high purity and scalability, enabling the company to produce millions of doses with shorter production cycles.

Generation Bio (Nasdaq: GBIO) will have CEO Geoff McDonough participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 10th at 11:00 a.m. ET in New York. A live webcast of the event will be accessible on the investor section of the company's website, with a replay available for 30 days afterwards.

The company focuses on innovative genetic medicines for rare and prevalent diseases using a unique DNA construct and delivery system aimed at providing durable treatments.